Udit Batra, currently CEO and President of Merck Millipore, has been appointed to lead the combined life science business of Merck Millipore and Sigma-Aldrich once the acquisition of Sigma-Aldrich has been successfully completed.
The planned US$ 17 billion transaction remains subject to customary closing conditions and regulatory approvals, which the company expects to have completed in mid-2015. Until then, Merck Millipore and Sigma-Aldrich will continue to operate as separate companies with Udit Batra and Rakesh Sachdev, President and CEO of Sigma-Aldrich, running both organisations independently. Rakesh Sachdev will serve in an advisory capacity, as needed, to ensure a smooth transition.
Karl-Ludwig Kley, Chairman of the Executive Board of Merck said, â€œThe appointment marks another important step in the acquisition of Sigma-Aldrich as it provides stable and strong leadership and continued customer focus during the crucial months of integration planning and beyond.â€
Udit Batra, has served as CEO and President of Merckâ€™s life science business Merck Millipore since March 2014. He joined Merck in 2011 to head the Groupâ€™s Consumer Health business. Prior to that, Udit Batra worked at Novartis Vaccines and Diagnostics, where he was head of Global Public Health and Market Access. He served in a range of executive management positions at Novartis, including global Head of Corporate Strategy and Country President for the Pharma Business in Australia.